INDIA – US-based molecular diagnostics company Cepheid has made its India debut with the launch of a 77,000-square-foot manufacturing unit in Bengaluru, the capital of Karnataka.
Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, Tuberculosis (TB) and emerging infectious diseases, healthcare-associated infectious diseases, oncology, and human genetics.
The American molecular diagnostics company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings.
Cepheid’s GeneXpert systems and Xpert tests automate highly complex and time-consuming manual procedures, providing a better way for institutions of any size to perform world-class PCR testing.
It has almost 50,000 GeneXpert Systems installed globally, including systems across 35 states and union territories in India.
With the launch of its first manufacturing unit in Mahadeva Kodigehalli, Cepheid will manufacture its industry-leading Xpert tuberculosis testing cartridges for the Indian market and beyond.
“This marks a significant milestone for Cepheid as it strengthens the company’s commitment to providing accessible and high-quality molecular diagnostic solutions to health care providers and patients in the region,” the company said in a statement.
The US-based firm pointed out that it will strengthen the broader molecular diagnostics production capabilities in the country.
In line with the Government of India’s “Make in India” policy, the local manufacturing of components will make Cepheid’s multidrug-resistant tuberculosis kits more accessible in India.
The manufacturing facility was inaugurated by Dr. K. Sudhakar, Minister for Health & Family Welfare and Medical Education, Govt. of Karnataka, and Laurent Bellon, Senior Vice President, Operations, Cepheid USA.
Moreover, the inauguration ceremony witnessed the participation of Srinath Venkatesh, President, Danaher India, and Mr. Ravikumar Venkataraman, Vice President, Danaher India Development Center.
“The Make in India program represents our vision of furthering India’s growth and development in the molecular diagnostic ecosystem,” stated Laurent Bellon, Senior Vice President, Operations, Cepheid USA.
He further said that the launch of the new manufacturing unit in India will build upon the country’s efforts to improve healthcare outcomes and eliminate TB.
The Cepheid manufacturing project in India was initiated in 2018 to support the dynamic Indian market.
“We are thrilled to announce the launch of our first manufacturing unit in India as it illustrates our strong commitment to the country,” underscored Laurent Bellon.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
